Biosite and FivePrime in diagnostics and therapeutics agreement:
This article was originally published in Clinica
Executive Summary
Biosite has teamed up with fellow California firm Prime Therapeutics to evaluate disease targets for potential diagnostic and therapeutic products. Under the collaboration, FivePrime, which has a comprehensive protein discovery programme, will provide Biosite with access to its selected functional disease targets for use in developing diagnostics. In exchange, FivePrime, of San Francisco, will get access to San Diego-based Biosite's Omniclonal antibodies for selected targets to accelerate its therapeutic research efforts.